» Articles » PMID: 2498144

Persistent Complement Activation in Submucosal Blood Vessels of Active Inflammatory Bowel Disease: Immunohistochemical Evidence

Overview
Specialty Gastroenterology
Date 1989 Jul 1
PMID 2498144
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Extensively washed and ethanol-fixed colonic specimens from 10 patients with ulcerative colitis, 3 patients with Crohn's disease of the colon, and 8 histologically normal controls were examined by two-color immunohistochemistry with monoclonal antibody to a neoepitope in the terminal complement complex combined with antiserum to factor VIII-related antigen (von Willebrand's factor), C3c, C3d, or C5. An alternative combination was monoclonal antibody to S-protein and antiserum to C9. Submucosal vessel walls in both normal and diseased colon showed parallel positivity for C3d, C5, C9, terminal complement complex, and S-protein, but the staining intensity and the proportion of positive vessels were significantly higher in inflammatory bowel disease than in controls. In addition, there was significantly more C3c reactivity associated with the terminal complement complex-positive submucosal vessels of active inflammatory bowel disease lesions than in histologically normal colon. Vascular C activation may therefore be a continuous process in active inflammatory bowel disease lesions, presumably related to the degree of inflammation and immune complex formation.

Citing Articles

The neoepitope of the complement C5b-9 Membrane Attack Complex is formed by proximity of adjacent ancillary regions of C9.

Bayly-Jones C, Ho B, Lau C, Leung E, DAndrea L, Lupton C Commun Biol. 2023; 6(1):42.

PMID: 36639734 PMC: 9838529. DOI: 10.1038/s42003-023-04431-y.


Collectin-11 (CL-11) Is a Major Sentinel at Epithelial Surfaces and Key Pattern Recognition Molecule in Complement-Mediated Ischaemic Injury.

Nauser C, Howard M, Fanelli G, Farrar C, Sacks S Front Immunol. 2018; 9:2023.

PMID: 30237800 PMC: 6136055. DOI: 10.3389/fimmu.2018.02023.


A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.

Elvington M, Blichmann P, Qiao F, Scheiber M, Wadsworth C, Luzinov I Clin Exp Immunol. 2014; 177(2):500-8.

PMID: 24730624 PMC: 4226601. DOI: 10.1111/cei.12350.


Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice.

Aomatsu T, Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H J Clin Biochem Nutr. 2013; 52(1):72-5.

PMID: 23341701 PMC: 3541422. DOI: 10.3164/jcbn.12-63.


Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.

Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, Tomlinson S J Immunol. 2012; 188(12):6309-18.

PMID: 22566568 PMC: 3370107. DOI: 10.4049/jimmunol.1200553.